Shorter course of radiation for breast cancer offers patients important benefit
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center report that a shorter course of whole breast radiation therapy for early stage breast cancer results in less toxicity and improved quality of life compared with a longer course of treatment.
They believe this information should be included in shared decision-making discussions with breast cancer patients.
Radiation treatment historically is given in smaller doses over a longer period of time (conventionally fractionated whole breast irradiation [CF-WBI]), rather than higher doses of radiation administered over a shorter time period (hypofractionated whole breast irradiation [HF-WBI]).
Older studies on the shorter treatment times produced disappointing results; however, the technology used in those studies is now antiquated.
With the use of modern technology, recurrence outcomes and survival rates are now equal yet use of the shorter treatment is slow to catch on.
Participants in the study reported less difficulty in managing their families’ needs, which is a major priority for many women.
The researchers believe their study demonstrates that HF-WBI is not just an option for patients; it should be considered as a preferred starting point in discussions with patients who need whole breast radiation. In addition, organizations such as ASTRO and NCCN should consider expanding their recommendations to include HF-WBI.
Shorter course of whole breast radiation therapy for early stage breast cancer results in less toxicity and improved quality of life.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|